Development asset linked to Xuanwu Hospital in public FDA and regional records.
pharma · Intracerebral Hemorrhage
Xuanwu Hospital
Xuanwu Hospital, Beijing
Xuanwu Hospital drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Beijing, CN HQ
117 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Beijing, CN
- Employees
- 117
- Programs
- 1
- Drugs
- 2
- Patents
- 0
Xuanwu Hospital pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Xuanwu Hospital drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
dimethyl fumarate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Kelch-like ECH-associated protein 1.
- Target
- Kelch-like ECH-associated protein 1
- Mechanism
- Kelch-like ECH-associated protein 1 inhibitor